Evidence map›Paper›PMID 34067779›Full record

ArticleBiomedicines2021

Radiotherapy in Follicular Lymphoma Staged by

Imke E Karsten, Gabriele Reinartz, Michaela Pixberg, Kai Kröger, Michael Oertel, Birte Friedrichs, Georg Lenz, Hans Theodor Eich

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. PET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  2. Article
  3. Article
  4. Duodenal-type follicular lymphoma inAmerican journal of nuclear medicine and molecular imaging · 2023
    Article
  5. New Insights in Radiotherapy.Biomedicines · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Imke E KarstenDepartment of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.ORCID 0000-0003-3453-6818
Gabriele ReinartzDepartment of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.ORCID 0000-0002-4869-5986
Michaela PixbergDepartment of Nuclear Medicine, University Hospital of Muenster, 48149 Muenster, Germany.
Kai KrögerDepartment of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.
Michael OertelDepartment of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.
Birte FriedrichsDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, 48149 Muenster, Germany.
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital of Muenster, 48149 Muenster, Germany.
Hans Theodor EichDepartment of Radiation Oncology, University Hospital of Muenster, 48149 Muenster, Germany.
University Hospital Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This retrospective study examined the role of

Indexed as

18F-FDG-PET/CTchemotherapyfollicular lymphomanon-Hodgkin lymphomaoncological imagingradiation therapytherapeutic evaluation

Identifiers

PMID34067779
PMCPMC8156324
OpenAlexW3160140965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.